Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch
Status:
Not yet recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
Combination antiretroviral therapy (cART) HIV treatments are associated with increased
quality of life, and a normalisation of life expectancy in people living with HIV. However,
long-term use of cART can lead to side-effects through exposure to drug-related toxicity.
For this reason researchers are interested in looking at alternative therapies that might
expose patients to fewer and less severe side effects while providing the same quality of
care as antiretroviral therapies most often used to treat HIV.
The purpose of this study is to investigate if the study drug combination that is being
tested (doravirine + dolutegravir) is safe compared with other triple cART regimens.